Alector, Inc. Common Stock
ALEC Real Time Price USDRecent trades of ALEC by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ALEC's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Anti-trem1 antibodies and methods of use thereof Oct. 08, 2024
-
Patent Title: Anti-sirp-beta1 antibodies and methods of use thereof Aug. 13, 2024
-
Patent Title: Siglec transgenic mice and methods of use thereof Jun. 11, 2024
-
Patent Title: Siglec-9 ecd fusion molecules May. 21, 2024
-
Patent Title: Anti-siglec-5 antibodies and methods of use thereof Apr. 23, 2024
-
Patent Title: Anti-mertk antibodies and methods of use thereof Feb. 13, 2024
-
Patent Title: Anti-sirp-alpha antibodies and methods of use thereof Oct. 10, 2023
-
Patent Title: Anti-siglec-9 antibodies and methods of use thereof Jun. 06, 2023
-
Patent Title: Anti-ms4a4a antibodies and methods of use thereof Jun. 06, 2023
-
Patent Title: Anti-trem2 antibodies and methods of use thereof Apr. 25, 2023
-
Patent Title: Anti-trem1 antibodies and methods of use thereof Oct. 18, 2022
-
Patent Title: Anti-ms4a4a antibodies and methods of use thereof Oct. 18, 2022
-
Patent Title: Transgenic mice expressing human trem proteins and methods of use thereof Oct. 18, 2022
-
Patent Title: Anti-tmem106b antibodies and methods of use thereof Sep. 13, 2022
-
Patent Title: Anti-sortilin antibodies and methods of use thereof Jul. 26, 2022
-
Patent Title: Anti-siglec-7 antibodies and methods of use thereof Jul. 19, 2022
-
Patent Title: Anti-siglec-5 antibodies and methods of use thereof Jun. 14, 2022
-
Patent Title: Methods of use of anti-sortilin antibodies for treating a disease, disorder, or injury May. 24, 2022
-
Patent Title: Anti-sirpa antibodies and methods of use thereof May. 03, 2022
-
Patent Title: Anti-cd33 antibodies and methods of use thereof Feb. 22, 2022
-
Patent Title: Methods of increasing progranulin levels using anti-sortilin antibodies Dec. 28, 2021
-
Patent Title: Isolated nucleic acids encoding anti-sortilin antibodies Nov. 30, 2021
-
Patent Title: Anti-cd33 antibodies and methods of use thereof Nov. 16, 2021
-
Patent Title: Siglec transgenic mice and methods of use thereof Oct. 19, 2021
-
Patent Title: Anti-cd33 antibodies and methods of use thereof Oct. 05, 2021
-
Patent Title: Anti-trem2 antibodies and methods of use thereof Aug. 10, 2021
-
Patent Title: Chimeric receptors and methods of use thereof Dec. 29, 2020
-
Patent Title: Methods of screening for sortilin binding antagonists Dec. 01, 2020
-
Patent Title: Anti-siglec-9 antibodies and methods of use thereof Oct. 13, 2020
-
Patent Title: Anti-cd33 antibodies and methods of use thereof Jul. 14, 2020
-
Patent Title: Anti-trem2 antibodies and methods of use thereof Jun. 09, 2020
-
Patent Title: Anti-siglec-7 antibodies and methods of use thereof Mar. 17, 2020
-
Patent Title: Anti-sortilin antibodies and methods of use thereof Oct. 01, 2019
-
Patent Title: Anti-sortilin antibodies and methods of use thereof Jun. 04, 2019
-
Patent Title: Anti-sortilin antibodies and methods of use thereof Oct. 02, 2018
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of ALEC in WallStreetBets Daily Discussion
Recent insights relating to ALEC
Recent picks made for ALEC stock on CNBC
ETFs with the largest estimated holdings in ALEC
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ALEC Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.